# Didymin Suppresses Microglia Pyroptosis and Neuroinflammation Through the Asc/Caspase-1/GSDMD Pathway Following Experimental Intracerebral Hemorrhage

**Authors:** Lingui Gu, Mingjiang Sun, Ruihao Li, Xingyu Zhang, Yihao Tao, Ye Yuan, Xu Luo, Zongyi Xie

PMC · DOI: 10.3389/fimmu.2022.810582 · 2022-01-27

## TL;DR

Didymin reduces brain inflammation and injury after intracerebral hemorrhage by suppressing microglial pyroptosis through a specific molecular pathway.

## Contribution

Didymin's novel anti-pyroptosis and anti-neuroinflammation effects via the Asc/Caspase-1/GSDMD pathway after ICH are demonstrated.

## Key findings

- Didymin improved neurobehavioral outcomes and reduced brain swelling after ICH.
- Didymin suppressed microglial pyroptosis and inflammatory molecule expression.
- Rkip upregulation by Didymin inhibits the inflammasome and neuroinflammation.

## Abstract

Neuroinflammation has been proven to exert an important effect on brain injury after intracerebral hemorrhage (ICH). Previous studies reported that Didymin possessed anti-inflammatory properties after acute hepatic injury, hyperglycemia-induced endothelial dysfunction, and death. However, the role of Didymin in microglial pyroptosis and neuroinflammation after ICH is unclear. The current study aimed to investigate the effect of Didymin on neuroinflammation mediated by microglial pyroptosis in mouse models of ICH and shed some light on the underlying mechanisms. In this study, we observed that Didymin treatment remarkably improved neurobehavioral performance and decreased BBB disruption and brain water content. Microglial activation and neutrophil infiltration in the peri-hematoma tissue after ICH were strikingly mitigated by Didymin as well. At the molecular level, administration of Didymin significantly unregulated the expression of Rkip and downregulated the expression of pyroptotic molecules and inflammatory cytokines such as Nlrp3 inflammasome, GSDMD, caspase-1, and mature IL-1β, TNF-α, and MPO after ICH. Besides, Didymin treatment decreased the number of Caspase-1-positive microglia and GSDMD-positive microglia after ICH. Inversely, Locostatin, an Rkip-specific inhibitor, significantly abolished the anti-pyroptosis and anti-neuroinflammation effects of Didymin. Moreover, Rkip binding with Asc could interrupt the activation and assembly of the inflammasome. Mechanistically, inhibition of Caspase-1 by VX-765 attenuated brain injury and suppressed microglial pyroptosis and neuroinflammation by downregulation of GSDMD, mature IL-1β, TNF-α, and MPO based on Locostatin-treated ICH. Taken together, Didymin alleviated microglial pyroptosis and neuroinflammation, at least in part through the Asc/Caspase-1/GSDMD pathway via upregulating Rkip expression after ICH. Therefore, Didymin may be a potential agent to attenuate neuroinflammation via its anti-pyroptosis effect after ICH.

## Linked entities

- **Genes:** PEBP1 (phosphatidylethanolamine binding protein 1) [NCBI Gene 5037], NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548], GSDMD (gasdermin D) [NCBI Gene 79792], Caspase1 (caspase-1) [NCBI Gene 692604], IL1B (interleukin 1 beta) [NCBI Gene 3553], TNF (tumor necrosis factor) [NCBI Gene 7124], MPO (myeloperoxidase) [NCBI Gene 4353], STS (steroid sulfatase) [NCBI Gene 412]
- **Chemicals:** Didymin (PubChem CID 16760075), Locostatin (PubChem CID 5702600), VX-765 (PubChem CID 11398092)
- **Diseases:** intracerebral hemorrhage (MONDO:0013792)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Tmem119 (transmembrane protein 119) [NCBI Gene 231633] {aka obif}, Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}, Pebp1 (phosphatidylethanolamine binding protein 1) [NCBI Gene 23980] {aka HCNP, Pbp, Pbp1, Pbpr, Rkip}, P9Ehs1 (protein, Chr 9, NIEHS 1) [NCBI Gene 109957], Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Casp1 (caspase 1) [NCBI Gene 12362] {aka ICE, Il1bc}, Nlrp3 (NLR family, pyrin domain containing 3) [NCBI Gene 216799] {aka AGTAVPRL, AII/AVP, Cias1, FCAS, FCU, MWS}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, Gsdmd (gasdermin D) [NCBI Gene 69146] {aka 1810036L03Rik, DF5L, Dfna5l, GsdmD-1, Gsdmdc1, M2-4}, Pycard (PYD and CARD domain containing) [NCBI Gene 66824] {aka 9130417A21Rik, Asc, CARD5, TMS-1, TNS1, masc}, Iba1 (induction of brown adipocytes 1) [NCBI Gene 114737], Il18 (interleukin 18) [NCBI Gene 16173] {aka Igif, Il-18}, Gfap (glial fibrillary acidic protein) [NCBI Gene 14580], Sts (steroid sulfatase) [NCBI Gene 20905] {aka ArsC}, Mpo (myeloperoxidase) [NCBI Gene 17523] {aka mKIAA4033}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, CASP1 (caspase 1) [NCBI Gene 834] {aka ICE, IL1BC, P45}
- **Diseases:** colitis (MESH:D003092), endothelial dysfunction (MESH:D014652), disruption (MESH:D019958), inflammation (MESH:D007249), cerebral ischemia (MESH:D002545), BBB disruption (MESH:C538387), neurological impairments (MESH:D009422), ulcerative colitis (MESH:D003093), neuroblastoma (MESH:D009447), ICH (MESH:D002543), central nervous system (CNS) diseases (MESH:D002493), neurodegenerative diseases (MESH:D019636), oxidative damage (MESH:D004194), PD (MESH:D010300), Neurobehavioral Deficits (MESH:D019954), EAE (MESH:D004681), Hematoma (MESH:D006406), acute liver injury (MESH:D017114), hyperglycemia (MESH:D006943), Neurological deficits (MESH:D009461), cancers (MESH:D009369), brain injury (MESH:D001930), Neuroinflammation (MESH:D000090862), AD (MESH:D000544), Mortality (MESH:D003643), MS (MESH:D009103), Brain Edema (MESH:D001929), acute hepatic injury (MESH:D056486), inflammatory cytokines (MESH:D000080424), hemorrhagic stroke (MESH:D000083302)
- **Chemicals:** FITC (MESH:D016650), flavonoid (MESH:D005419), bicinchoninic acid (MESH:C047117), CO2 (MESH:D002245), VX-765 (MESH:C520022), phenylmethylsulfonyl fluoride (MESH:D010664), streptomycin (MESH:D013307), free radicals (MESH:D005609), DTT (MESH:D004229), Co (MESH:D003035), agarose (MESH:D012685), Locostatin (MESH:C529490), sucrose (MESH:D013395), glycerol (MESH:D005990), DAPI (MESH:C007293), penicillin (MESH:D010406), LPS (MESH:D008070), Water (MESH:D014867), hydrogen peroxide (MESH:D006861), TCA (MESH:D014238), pentobarbital (MESH:D010424), NaCl (MESH:D012965), PBS (MESH:D007854), CCl4 (MESH:D002251), DMEM (-), ethylenediaminetetraacetic acid (MESH:D004492), EB (MESH:D005070), SDS (MESH:D012967), NP40 (MESH:C010615), PVDF (MESH:C024865), Didymin (MESH:C552234), fatty acid (MESH:D005227), Triton X-100 (MESH:D017830), paraformaldehyde (MESH:C003043), glucose (MESH:D005947), DMSO (MESH:D004121),  (MESH:D006027)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** BV-2 — Mus musculus (Mouse), Transformed cell line (CVCL_0182), C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU)

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC8828494/full.md

---
Source: https://tomesphere.com/paper/PMC8828494